Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Incyte Corporation
Daiichi Sankyo
NextCure, Inc.
Fred Hutchinson Cancer Center
OncoNano Medicine, Inc.
Nektar Therapeutics
Herlev Hospital
Ludwig Institute for Cancer Research
Incyte Corporation
Duke University
Incyte Corporation